Share-based Payment Arrangement, Expense of Oruka Therapeutics, Inc. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oruka Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • Oruka Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $10,165,000, a 13% increase year-over-year.
  • Oruka Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $25,246,000, a 154% increase year-over-year.
  • Oruka Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,919,000, a 2075% increase from 2023.
  • Oruka Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $686,000, a 23% increase from 2022.
  • Oruka Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $556,000, a 12% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Oruka Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $25,246,000 $10,165,000 +$1,164,000 +13% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $24,082,000 $5,077,000 +$4,394,000 +643% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $19,688,000 $4,883,000 +$4,769,000 +4183% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $14,919,000 $5,121,000 +$4,980,000 +3532% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $9,939,000 $9,001,000 +$8,847,000 +5745% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $1,092,000 $683,000 +$496,000 +265% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $596,000 $114,000 -$90,000 -44% 01 Jan 2024 31 Mar 2024 10-Q 25 Apr 2024 2024 Q1
Q4 2023 $686,000 $141,000 +$21,000 +18% 01 Oct 2023 31 Dec 2023 10-K 01 Feb 2024 2023 FY
Q3 2023 $665,000 $154,000 +$57,000 +59% 01 Jul 2023 30 Sep 2023 10-Q 18 Oct 2023 2023 Q3
Q2 2023 $608,000 $187,000 +$15,000 +8.7% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $593,000 $204,000 +$37,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 25 Apr 2024 2024 Q1
Q4 2022 $556,000 $120,000 +$1,000 +0.84% 01 Oct 2022 31 Dec 2022 10-K 01 Feb 2024 2023 FY
Q3 2022 $555,000 $97,000 -$7,000 -6.7% 01 Jul 2022 30 Sep 2022 10-Q 18 Oct 2023 2023 Q3
Q2 2022 $562,000 $172,000 +$39,000 +29% 01 Apr 2022 30 Jun 2022 10-Q 21 Jul 2023 2023 Q1
Q1 2022 $523,000 $167,000 +$26,000 +18% 01 Jan 2022 31 Mar 2022 10-Q 24 Apr 2023 2023 Q1
Q4 2021 $497,000 $119,000 +$101,000 +561% 01 Oct 2021 31 Dec 2021 10-K 24 Feb 2023 2022 FY
Q3 2021 $396,000 $104,000 +$99,000 +1980% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 $297,000 $133,000 +$129,000 +3225% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $168,000 $141,000 +$125,000 +781% 01 Jan 2021 31 Mar 2021 10-Q 02 May 2022 2022 Q1
Q4 2020 $43,000 $18,000 -$9,000 -33% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 $52,000 $5,000 -$24,000 -83% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $76,000 $4,000 -$41,000 -91% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $117,000 $16,000 -$34,000 -68% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $151,000 $27,000 -$31,000 -53% 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $182,000 $29,000 -$29,000 -50% 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $211,000 $45,000 -$15,000 -25% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $226,000 $50,000 -$47,000 -48% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $273,000 $58,000 -$61,000 -51% 01 Oct 2018 31 Dec 2018 10-K 18 Feb 2020 2019 FY
Q3 2018 $334,000 $58,000 -$61,000 -51% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $395,000 $60,000 -$59,000 -50% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $454,000 $97,000 -$4,000 -4% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $458,000 $119,000 +$148,000 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 $310,000 $119,000 -$148,000 -55% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $458,000 $119,000 -$64,000 -35% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $522,000 $101,000 -$54,000 -35% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $576,000 $29,000 -$174,000 -120% 01 Oct 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
Q3 2016 $750,000 $267,000 +$118,000 +79% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $632,000 $183,000 +$8,000 +4.6% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $624,000 $155,000 +$25,000 +19% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $599,000 $145,000 -$11,000 -7.1% 01 Oct 2015 31 Dec 2015 10-K 21 Mar 2017 2016 FY
Q3 2015 $610,000 $149,000 -$12,000 -7.5% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $622,000 $175,000 +$3,000 +1.7% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $619,000 $130,000 -$28,000 -18% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1
Q4 2014 $647,000 $156,000 -$2,000 -1.3% 01 Oct 2014 31 Dec 2014 10-K 17 Mar 2016 2015 FY
Q3 2014 $649,000 $161,000 +$112,000 +229% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $537,000 $172,000 +$138,000 +406% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $399,000 $158,000 +$116,000 +276% 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015 2015 Q1
Q4 2013 $283,000 $158,000 +$95,000 +151% 01 Oct 2013 31 Dec 2013 10-K 19 Mar 2015 2014 FY
Q3 2013 $188,000 $49,000 -$25,000 -34% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $213,000 $34,000 -$44,000 -56% 01 Apr 2013 30 Jun 2013 10-Q 13 Aug 2014 2014 Q2
Q1 2013 $257,000 $42,000 -$49,000 -54% 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014 2014 Q1
Q4 2012 $306,000 $63,000 01 Oct 2012 31 Dec 2012 10-K 20 Mar 2014 2013 FY
Q3 2012 $74,000 -$5,000 -6.3% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013 2013 Q3
Q2 2012 $78,000 +$3,000 +4% 01 Apr 2012 30 Jun 2012 10-Q 13 Aug 2013 2013 Q2
Q1 2012 $91,000 01 Jan 2012 31 Mar 2012 10-Q 13 May 2013 2013 Q1
Q3 2011 $79,000 01 Jul 2011 30 Sep 2011 10-Q 13 Nov 2012 2012 Q3
Q2 2011 $75,000 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012 2012 Q2

Oruka Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,919,000 +$14,233,000 +2075% 06 Feb 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $686,000 +$130,000 +23% 01 Jan 2023 31 Dec 2023 10-K 01 Feb 2024 2023 FY
2022 $556,000 +$59,000 +12% 01 Jan 2022 31 Dec 2022 10-K 01 Feb 2024 2023 FY
2021 $497,000 +$454,000 +1056% 01 Jan 2021 31 Dec 2021 10-K 24 Feb 2023 2022 FY
2020 $43,000 -$108,000 -72% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
2019 $151,000 -$122,000 -45% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $273,000 -$185,000 -40% 01 Jan 2018 31 Dec 2018 10-K 18 Feb 2020 2019 FY
2017 $458,000 -$118,000 -20% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
2016 $576,000 -$23,000 -3.8% 01 Jan 2016 31 Dec 2016 10-K 22 Mar 2018 2017 FY
2015 $599,000 -$48,000 -7.4% 01 Jan 2015 31 Dec 2015 10-K 21 Mar 2017 2016 FY
2014 $647,000 +$364,000 +129% 01 Jan 2014 31 Dec 2014 10-K 17 Mar 2016 2015 FY
2013 $283,000 -$23,000 -7.5% 01 Jan 2013 31 Dec 2013 10-K 19 Mar 2015 2014 FY
2012 $306,000 -$2,000 -0.65% 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2014 2013 FY
2011 $308,000 01 Jan 2011 31 Dec 2011 10-K 21 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.